A 2026 review of systemic acne care beyond isotretinoin finds different evidence levels for three drugs. Spironolactone has randomized-trial support in adult women, metformin helps mainly with PCOS or insulin resistance, and bicalutamide remains experimental. Persistent adult acne means acne continuing from the teen years past age 25. It accounts for most adult female cases and is often mild-to-moderate inflammatory disease with a strong effect on daily life.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why look beyond isotretinoin?
- What did the spironolactone trials test?
- Who is metformin for?
- Why does bicalutamide remain experimental?
- What should adults with persistent acne discuss next?
Why look beyond isotretinoin?
Isotretinoin works well for severe acne but carries safety and monitoring demands. According to the Dermatology Times summary of the 2026 narrative review, authors therefore revisited other systemic options including sarecycline, spironolactone, hormonal therapies and metabolic drugs such as metformin the Dermatology Times review summary.
The review frames therapy choice around patient traits rather than one drug for all. Hormone-driven disease points toward antiandrogen approaches. Metabolic traits such as insulin resistance point toward a different path.
What did the spironolactone trials test?
The SAFA trial focused on women aged 18 and older with persistent acne for whom oral antibiotics were the next step. According to the University of Southampton/NIHR summary, 410 participants were randomized 1:1 to spironolactone 50 mg daily rising to 100 mg daily from week 6 to 24 or matched placebo the Southampton trial summary. Benefit built slowly rather than in the first weeks.
According to the BMJ report, spironolactone improved self-reported acne and quality of life versus placebo, with the gap widening between week 12 and week 24 and tolerability supporting continued use the BMJ trial report. A second trial, FASCE, tested a higher dose against an antibiotic. The INSERM/British Journal of Dermatology report randomized 133 adult women to spironolactone 150 mg daily for six months or doxycycline 100 mg daily for three months. Success on Investigator Global Assessment was greater with spironolactone at six months.
Who is metformin for?
Metformin is not a general acne pill. The 2026 review summary links its benefit chiefly to polycystic ovary syndrome or insulin resistance, through lower IGF-1 and androgen signaling. Metabolic phenotyping is therefore proposed as a way to select patients.
A Springer Medicine systematic review and meta-analysis found less acne after metformin in PCOS patients. The same analysis noted different acne scales, doses and treatment lengths across studies. Those differences limit direct comparison and extension beyond PCOS.
Why does bicalutamide remain experimental?
Bicalutamide evidence for acne comes from very small datasets. A frequently cited pilot involved only 17 patients with female hair loss, with reported improvement in accompanying seborrhea, acne and hirsutism. Reviewers called for larger trials to set dosing and safety.
Safety concerns are substantial. According to U.S. Food and Drug Administration labeling, bicalutamide warns of severe hepatic injury and fatal liver failure needing baseline and periodic transaminase checks, plus fetal harm with contraindication in pregnancy and no indication in women for non-life-threatening conditions the FDA DailyMed label.
What should adults with persistent acne discuss next?
Start by confirming the pattern and possible drivers. Persistent disease differs from late-onset disease, and cycles, excess hair growth, irregular periods, weight change and prior antibiotic use can shape the choice.
Bring a focused history to the visit: Ask whether a spironolactone course, metabolic workup or antibiotic-sparing plan fits your case. Do not seek bicalutamide outside a supervised trial setting because dosing is unsettled and liver and pregnancy risks require monitoring.
- age acne continued past 25 and prior systemic treatments
- signs of high androgens or PCOS, if present
- blood sugar, insulin or weight concerns, if present
- pregnancy plans, contraception and liver history
- current skin routine and tolerance for slow response
You Might Also Like
- Limited Topical Spironolactone Evidence in the 2026 Review: Study Design and Evidence Limits for Adults With Persistent Acne
- Adult Female Acne Antiandrogen Treatments in a 2026 Review: Study Design and Evidence Limits for Adults With Persistent Acne
- Fish Oil With Low-Dose Isotretinoin in a 2026 Randomized Trial: Study Design and Evidence Limits for Adults With Persistent Acne